RNA CAR T Shows Promise for Myasthenia Gravis
Here’s a breakdown of the key facts from the provided text, focusing on the Descartes-08 treatment for Myasthenia Gravis (MG):
What is Descartes-08?
It’s a BCMA-directed autologous rCAR T-cell therapy. This means it uses the patient’s own T-cells, engineered to target a specific protein (BCMA) and fight the disease.
Unique Feature: Unlike customary CAR-T therapies, Descartes-08 undergoes ex vivo (outside the body) T-cell proliferation. This allows for controlled dosing and avoids the need for lymphodepleting chemotherapy. It can be administered in an outpatient setting.
Dosage: 52.5 x 106 cells/kg, given in 6 weekly infusions.
Study Details:
Phase: 1/2a study
Location: Community and academic medical centers
Patients: 7 total (5 female)
MG Types: Included patients wiht different antibody types:
AChR Ab+ (3 patients)
MuSK Ab+ (2 patients)
Seronegative (1 patient)
key Results & Improvements:
Disease Severity Betterment: Observed as early as 3 months after starting treatment.
Treatment Response: 72% of patients maintained their response at 12 months.
prednisone Reduction: Patients reduced their median prednisone dose from 17.5 mg/day to 12.5 mg/day by month 12.
No IVIG Needed: No patients required intravenous immunoglobulin during the year of follow-up.
Improvements on Scales (Mean Changes):
Month 9:
MG-ADL: −6.3 (95% CI, −3.5 to −9.1)
MGC: −16.6 (95% CI, −13.4 to −19.5)
QMG: −8.4 (95% CI, −5.2 to -11.6)
QoL-15r: −12.0 (95% CI,−8.0 to −16.0)
Month 12 (5 of 7 patients):
MG-ADL: −4.6 (95% CI, -8.8 to −0.4)
MGC: -11.3 (95% CI,−18.0 to −4.6)
QMG −6.3 (95% CI, −10.5 to −2.0)
Clinically Meaningful Improvement: Defined as at least a 2-point improvement on MG-ADL, MGC, and QMG scales.
Safety:
No reports of anaphylaxis or hematologic toxicity.
Immunoglobulin levels did not significantly decrease.
Scales Used for Evaluation:
MG-ADL: Myasthenia Gravis Activities of Daily Living
MGC: MG Composite
QMG: Quantitative Myasthenia Gravis
* qol-15r: MG quality of life 15-revised score